| Drug Name |
Dapagliflozin |
| Drug ID |
BADD_D00578 |
| Description |
Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor indicated for managing diabetes mellitus type 2.[A6757] When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose resorption in the proximal tubule of the nephron and causing glycosuria.[A6757] Dapagliflozin was approved by the FDA on Jan 08, 2014.[L6034] |
| Indications and Usage |
Dapagliflozin is indicated for adjunct management of glycemic control in patients with type 2 diabetes mellitus, in combination with diet and exercise. |
| Marketing Status |
Prescription |
| ATC Code |
A10BK01 |
| DrugBank ID |
DB06292
|
| KEGG ID |
D08897
|
| MeSH ID |
C529054
|
| PubChem ID |
9887712
|
| TTD Drug ID |
D01TNW
|
| NDC Product Code |
17228-6205; 50090-3482; 14501-0028; 55154-6932; 59285-012; 66529-0003; 54921-621; 55111-987; 69037-0027; 65727-073; 12783-1428; 50090-3481; 0310-6205; 17228-6210; 12783-1427; 54921-620; 55154-6933; 46708-897; 66064-1029; 50193-1427; 59651-135; 0310-6210; 66039-933 |
| Synonyms |
dapagliflozin | (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol | Farxiga | Forxiga | 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol | BMS 512148 | BMS512148 | BMS-512148 |
